PD-1 Inhibitors, Radiation Therapy, and Photodynamic Therapy Are Variable Options for Cutaneous Squamous Cell Carcinoma Treatment
Cutaneous squamous cell carcinoma is a skin cancer. The condition develops in the squamous cells that make up the middle and outer layers of the skin. According to one estimate, about 5.4 million basal and squamous cell skin cancers are diagnosed each year in the U.S. The condition can be difficult to diagnose because it resembles so many other types of skin cancers. The common characteristics include, benign intracranial mesothelioma, which affects the lining of the brain and spinal cord; squamous cell carcinoma, which affect the lymph nodes and tissues surrounding the body; and cervical cancer, which affect the cervix and its lymph nodes.
Cutaneous squamous cell carcinoma treatments include, curettage and electrodessication, laser therapy, photodynamic therapy, cryosurgery, excision, Mohs surgery, superficial radiation therapy, lymph node surgery, topical chemotherapy, and targeted drug treatment. In laser surgery, portions of the cancerous tissue are removed with a high-energy laser. Sometimes, all tumors are eliminated with this method, although this is not always the case. This procedure is often used when treating people who have only superficial tumors. The laser used in this treatment is very specific: it kills only cancerous tissue, preventing other healthy, normal tissue from being damaged.
In recent years, doctors have begun giving radiation therapy or photodynamic therapy for cutaneous squamous cell carcinoma treatment. Intravenous PD-1 inhibitor has also demonstrated potential in the treatment of the condition. In January 2021, the U.S. Food and Drug Administration accepted a Biologics License Application for retifanlimab, an investigational intravenous PD-1 inhibitor for the treatment of locally advanced or metastatic squamous cell carcinoma of the anal canal in adults. The product that induced durable responses in patients with locally advanced or metastatic squamous cell carcinoma of the anal canal, is developed by Incyte Corporation, the U.S-based pharmaceutical company that focuses on R&D and commercialization of proprietary therapeutics.
Comments
Post a Comment